Related Experiment Video
Updated: Jan 4, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
8.2K
System-based approaches as prognostic tools for glioblastoma
Manuela Salvucci1, Zaitun Zakaria1, Steven Carberry1
1Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, 123 St Stephen's Green, Dublin 2, Ireland.
BMC Cancer
|November 14, 2019
Summary
System medicine approaches model apoptosis to improve cancer treatment, particularly for glioblastoma. These methods offer new diagnostic and therapeutic strategies for personalized patient care.
Area of Science:
- Oncology
- Systems Biology
- Computational Biology
Background:
- Apoptosis evasion is a key feature of cancer, driving resistance to treatment.
- Personalized medicine requires effective strategies to confirm treatment efficacy and identify novel options.
- Systems medicine approaches model complex apoptosis pathways for holistic understanding.
Purpose of the Study:
- To review the development of systems medicine approaches for modeling apoptosis in cancer treatment.
- To emphasize the application of these approaches in aggressive brain cancer, glioblastoma.
Main Methods:
- Review of current literature on systems medicine and apoptosis modeling.
- Analysis of biochemical pathways involved in apoptosis.
- Integration of systems approaches with clinical and histopathological practices.
Main Results:
- Development of systems medicine tools to model apoptosis pathways in cancer.
- Specific focus on glioblastoma, an aggressive brain cancer.
- Demonstration of the potential for these models to impact cancer treatment.
Conclusions:
- Systems medicine offers a powerful approach to understanding and overcoming apoptosis resistance in cancer.
- New approaches highlight the potential of systems medicine to transform glioblastoma diagnosis and treatment.
- Integration of systems medicine into clinical practice is crucial for delivering personalized cancer care.
